Oral glucose tolerance test does not affect degree of hemoglobin glycation as measured by routine assay.


Journal

Annales d'endocrinologie
ISSN: 2213-3941
Titre abrégé: Ann Endocrinol (Paris)
Pays: France
ID NLM: 0116744

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 06 07 2020
revised: 16 11 2020
accepted: 25 11 2020
pubmed: 6 12 2020
medline: 5 11 2021
entrez: 5 12 2020
Statut: ppublish

Résumé

Hemoglobin A1c (HbA1c) is an accurate index of fluctuation in glycemia over the 2-3 months prior to quantitative assessment. During this time, hemoglobin (Hb) slowly glycates until it shows the properties of advanced glycation end-products. Glycation kinetics is intensified by prolonged glucose exposure. In subjects undergoing oral glucose tolerance testing (OGTT), immediately after ingestion, glucose is ostensibly transported by the glucose transporter 1 (GLUT1) to erythrocyte corpuscular hemoglobin. The earliest significant measurable level of hemoglobin glycation associated with this transportation is still not clear. We attempted to explore the early impact of short-term glucose load on HbA1c levels, because it is now known that transmembrane GLUT1-mediated glucose transport occurs immediately. A total of 88 participants (46 patients and 42 clinically healthy controls) underwent fasting plasma glucose quantitation during an OGTT. HbA1c, revealed by a monoclonal anti-glycation epitope antibody and adiponectin, was quantitated before (T0) and 2 hours (T120) after 80 g glucose ingestion. Wilcoxon test revealed that the HbA1c values did not significantly vary (P=0.15) during the OGTT, whereas glucose concentration varied strongly between T0 and T120. It is well known that quantitative estimation of HbA1c is informative for clinical care, independently of glucose level. The molecular mechanisms and dynamics by which glucose enters/exits red blood cells are incompletely known and may differ between individuals. We here show, for the first time, that HbA1c levels do not significantly increase during OGTT, supporting the view that non-enzymatic glycation of hemoglobin occurs slowly and that glycation during the 2 hours of an OGTT is insignificant.

Sections du résumé

BACKGROUND BACKGROUND
Hemoglobin A1c (HbA1c) is an accurate index of fluctuation in glycemia over the 2-3 months prior to quantitative assessment. During this time, hemoglobin (Hb) slowly glycates until it shows the properties of advanced glycation end-products. Glycation kinetics is intensified by prolonged glucose exposure. In subjects undergoing oral glucose tolerance testing (OGTT), immediately after ingestion, glucose is ostensibly transported by the glucose transporter 1 (GLUT1) to erythrocyte corpuscular hemoglobin. The earliest significant measurable level of hemoglobin glycation associated with this transportation is still not clear.
SUBJECTS AND METHODS METHODS
We attempted to explore the early impact of short-term glucose load on HbA1c levels, because it is now known that transmembrane GLUT1-mediated glucose transport occurs immediately. A total of 88 participants (46 patients and 42 clinically healthy controls) underwent fasting plasma glucose quantitation during an OGTT. HbA1c, revealed by a monoclonal anti-glycation epitope antibody and adiponectin, was quantitated before (T0) and 2 hours (T120) after 80 g glucose ingestion.
RESULTS RESULTS
Wilcoxon test revealed that the HbA1c values did not significantly vary (P=0.15) during the OGTT, whereas glucose concentration varied strongly between T0 and T120.
DISCUSSION CONCLUSIONS
It is well known that quantitative estimation of HbA1c is informative for clinical care, independently of glucose level. The molecular mechanisms and dynamics by which glucose enters/exits red blood cells are incompletely known and may differ between individuals. We here show, for the first time, that HbA1c levels do not significantly increase during OGTT, supporting the view that non-enzymatic glycation of hemoglobin occurs slowly and that glycation during the 2 hours of an OGTT is insignificant.

Identifiants

pubmed: 33278381
pii: S0003-4266(20)31304-4
doi: 10.1016/j.ando.2020.11.003
pii:
doi:

Substances chimiques

Adiponectin 0
Blood Glucose 0
Glucose Transporter Type 1 0
Glycated Hemoglobin A 0
Hemoglobins 0
SLC2A1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

545-550

Informations de copyright

Copyright © 2020 Labormedizinisches zentrum Dr. Risch. Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Nathalie Gilliéron (N)

Centre Medical VidyMed, Lausanne, Switzerland. Electronic address: urs.nydegger@risch.ch.

Andreas Hemmerle (A)

Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein.

Thomas Lung (T)

Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein.

Benjamin Sakem (B)

Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein.

Lorenz Risch (L)

Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein.

Martin Risch (M)

Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein; Central Laboratory, Kantonsspital Graubünden, Chur, Switzerland.

Urs E Nydegger (UE)

Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH